Labcorp: third-quarter earnings, operational risks, and insider trades
Labcorp Holdings Inc. filed its 10-Q report for the third quarter of 2026, reporting quarterly revenue of $3,810 million, a 6.9% increase from the previous year. The document detailed several operational risks, including those related to implementing an enterprise resource planning (ERP) system, labor relations, and animal research activities.
Key points
- For the quarter ended September 30, 2026, the company reported revenue of $3,810 million.
- In the 10-Q report, the company noted that implementing and operating its new ERP system poses operational risks.
- Director Richelle P. Parham sold 1,078 shares on the open market on October 30, 2026, at a weighted average price of $361.22.
Quarterly financial results
For the quarter ended September 30, 2026, the company reported revenue of $3,810 million. Year-to-date revenue reached $11,078.7 million, up 6.2% from the same period last year. Revenue in the Diagnostics (Dx) segment grew 6.5% to $2,948.9 million, while the Biopharmaceutical Laboratory Services (BLS) segment revenue rose 8.5% to $866.7 million.
Operational risks and upcoming presentations
In the 10-Q report, the company noted that implementing and operating its new ERP system poses operational risks. These include potential supply chain disruptions, transaction processing errors, and negative impacts on cash flow and liquidity. The company also highlighted threats related to potential employee unionization and possible reputational damage from animal rights activists.
Chief financial officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026.
Insider transactions
Director Richelle P. Parham sold 1,078 shares on the open market on October 30, 2026, at a weighted average price of $361.22.
Executives Bryan T. Vaughn and Akinbolade Oyegunwa converted derivative securities on November 1, 2026. On November 2, the company withheld shares from both executives to cover tax obligations related to vesting.
Additionally, on November 3, Bryan T. Vaughn filed a notice of a proposed sale of 306 shares under a plan adopted on March 8, 2026.
What to watch
Investors should monitor company updates on ERP implementation progress and its impact on operational stability. The company plans to release additional information on 2027 guidance, including the impact of CMS payment rates, in February 2027.
Original sources
- financial data (XBRL)
- 8-K filing, November 4, 2026
- 10-Q filing, October 30, 2026
- 4 filing, November 3, 2026
- 4 filing, November 3, 2026
- 4 filing, November 3, 2026
- 144 filing, November 3, 2026
- 8-K filing, September 22, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Labcorp
A notification in your browser or on your phone when we publish about Labcorp. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
